ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines (Q40524644)

21 September 2017

ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines (English)

1 reference

21 September 2017

Trina J Stewart

1

1 reference

21 September 2017

Debbie Drane

2

1 reference

21 September 2017

Jim Malliaros

3

1 reference

21 September 2017

Heidi Elmer

4

1 reference

21 September 2017

Karen M Malcolm

5

1 reference

21 September 2017

John C Cox

6

1 reference

21 September 2017

Stirling J Edwards

7

1 reference

21 September 2017

Ian H Frazer

8

1 reference

21 September 2017

Germain J P Fernando

9

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

21 September 2017

1 reference

21 September 2017

22

1 reference

21 September 2017

27-28

1 reference

21 September 2017

3738-3743

1 reference

The causal relation between human papillomavirus and cervical cancer

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Human papillomavirus—the most significant risk determinant of cervical intraepithelial neoplasia

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

inferred from DOI database lookup

7 January 2021

based on heuristic

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Immune responses to ISCOM formulations in animal and primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Functional aspects of iscoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

T Cell-Mediated and Non-Specific Inflammatory Mechanisms Contribute to the Skin Pathology of HPV 16 E6E7 Transgenic Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

Fc receptors are required in passive and active immunity to melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

ISCOMs and other saponin based adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.03.026

10.1016/J.VACCINE.2004.03.026

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference